GlassScriptPhysician profile
Katia C Korte
NPI 1083942270
$2,967.96
in general payments reported to CMS, 2019-2025
27 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $62.87 · 2021: $246 · 2022: $258 · 2023: $680 · 2024: $575 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $518.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $389.55 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $211.88 | 2023-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $179.39 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $169.00 | 2019-2025 | Arexvy, Shingrix |
| Shield Therapeutics INC | $123.36 | 2023-2025 | Accrufer |
| Inspire Medical Systems, INC. | $112.51 | 2025 | Inspire |
| Exact Sciences Corporation | $95.22 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $73.64 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.04 | 2022-2025 | Stiolto Respimat, Jardiance |
| Phathom Pharmaceuticals, INC. | $60.60 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $57.34 | 2019 | |
| Sumitomo Pharma America, INC. | $46.00 | 2025 | Gemtesa |
| Lucid Diagnostics INC. | $33.37 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $29.81 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $28.58 | 2023 | Eliquis |
| Corcept Therapeutics | $28.57 | 2024 | Korlym |
| Gilead Sciences, INC. | $23.81 | 2021 | |
| Medtronic, INC. | $22.51 | 2022 | |
| Abbott Laboratories | $20.74 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $18.13 | 2022 | |
| Seqirus USA INC | $17.35 | 2021 | |
| Mylan Specialty L.P. | $17.30 | 2022 | |
| Merck Sharp & Dohme LLC | $16.37 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $15.29 | 2021 | |
| Abbvie INC. | $13.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Korte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.